These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11796015)

  • 1. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
    Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
    J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
    Bera TK; Viner J; Brinkmann E; Pastan I
    Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
    Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
    Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
    J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
    Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
    Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
    Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM
    Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
    Li Q; Verschraegen CF; Mendoza J; Hassan R
    Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
    Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
    Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
    Reiter Y; Pastan I
    Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
    Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
    Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells.
    Bao W; Fu HJ; Xie QS; Wang L; Zhang R; Guo ZY; Zhao J; Meng YL; Ren XL; Wang T; Li Q; Jin BQ; Yao LB; Wang RA; Fan DM; Chen SY; Jia LT; Yang AG
    Gastroenterology; 2011 Dec; 141(6):2076-2087.e6. PubMed ID: 21925125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.